Calico Life Sciences, LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Calico Life Sciences, LLC
As Barron departs for new rejuvenation-focused biotech Altos Labs, GSK will be under pressure to ensure its R&D can continue to produce green shoots.
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
Private Company Edition: The allogeneic cell therapy developer founded by former Juno execs launched in January 2019 without disclosing its initial funding. Other recent venture capital mega-rounds include $192m for Orca, $170m for C4, $118m for Shattuck and $102m for GreenLight.
Emerging Company Profile: The start-up's Phase I and II studies look promising for stem cell therapy in treating aging frailty, a common condition that overlaps with Alzheimer's disease.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Calico Group LLC
- Calico LLC